NeoProgen, Inc. Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from the US Patent Office
Tuesday, April 13, 2021
BALTIMORE--(BUSINESS WIRE)--NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the United States Patent Office Patent No.: US 10.967,007 B2 “Cardiac Stem Cells for Cardiac Repair”. The innovation was developed by Dr. Sunjay Kaushal, a pediatric cardiac surgeon, while he was at the University of Maryland, Baltimore and NeoProgen is the exclusive licensee of the newly issued patent.
The patent claims describe methods for treating cardiac conditions with an exosome-based therapy (conditioned media) derived from neonatal cardiac stem cells. The unique approach that the company has taken to isolating the cells, culturing nMSCs, characterizing them by their secretome and exosome production, and improving cardiac function by administering allogeneic nMSCs to adults and children represents an exciting therapy for heart failure and other inflammatory diseases.
Read the full press release.